GlaxoSmithKline Sues Moderna For U.S. Patent Infringement Over mRNA Technology In Covid-19 Vaccines
Portfolio Pulse from Benzinga Newsdesk
GlaxoSmithKline (GSK) has filed a lawsuit against Moderna (MRNA) in the U.S. for patent infringement related to mRNA technology used in Covid-19 vaccines.
October 15, 2024 | 1:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
GlaxoSmithKline has initiated legal action against Moderna, claiming patent infringement over mRNA technology in Covid-19 vaccines.
The lawsuit could have financial implications for GSK if they win or settle, but the immediate impact on stock price is uncertain as legal processes are lengthy.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Moderna is being sued by GlaxoSmithKline for allegedly infringing on mRNA technology patents in their Covid-19 vaccines.
The lawsuit could negatively impact Moderna's stock due to potential financial liabilities and market perception of legal challenges.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90